What ENGAIN does

ENGAIN (주식회사 엔게인) is a privately held South Korean medical device company founded in December 2011 that specializes in the research, development, and manufacturing of medical devices built on proprietary biocompatible polymer synthetic materials. The company operates from its headquarters in Hwaseong-si, Gyeonggi-do, with manufacturing at KGMP-certified facilities in Dongtan and Sangweon, and employs between 11 and 50 people. It is led by CEO Go Young-guk (고영국) and has raised capital through more than 20 rights offerings between 2020 and 2026, indicating it is in a growth-financing phase rather than operating at scale.

ENGAIN's product portfolio is organized around three therapeutic pillars plus medical consumables. The embolization franchise includes EGgel (MFDS Class 3 approved 2016), EGbead (2017), and KIPZA fast-dissolving microparticles, all based on gelatin-based biomaterials used for vascular embolization procedures. The wound closure franchise centers on EGglue (MFDS Class 3 approved 2020) and Easyglue, both N-Butyl Cyanoacrylate (n-BCA) based skin adhesives. The varicose vein treatment franchise is anchored by NUVENA, a non-thermal non-tumescent (NTNT) adhesive closure system that received MFDS market approval on January 6, 2026. Adjacent medical consumables include Soft Fix PLUS drainage tube fixators, Bougie-36 surgical guides, and LAPA FIX laparoscopic instruments. The company also maintains a research direction in a color-change sensing diagnostic platform that is not yet commercialized.

ENGAIN generates revenue through direct B2B sales of medical devices to hospitals and healthcare facilities, with the majority of its confirmed customer base concentrated in Seoul's top 5 general hospitals as of 2019. It sells primarily through an enterprise field sales motion supplemented by a customer satisfaction hotline, and exports products to international markets including the Middle East and Europe following its 2018 overseas launch of EGgel. The company's competitive position rests on in-house polymer chemistry capabilities, accumulated MFDS Class 1, 2, and 3 regulatory approvals, ISO 13485:2016 and KGMP quality certifications, and a vertically integrated R&D-to-manufacturing model. Pricing is negotiated individually per institutional account and is not publicly disclosed.

Name

ENGAIN

Legal name

주식회사 엔게인

Website

https://engain.co.kr

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

ENGAIN is a South Korean medical device company founded in 2011 that develops and manufactures biocompatible polymer-based embolization agents, skin adhesives, and varicose vein treatment systems, selling directly to hospitals domestically and exporting to international markets.

Ownership category

akta.pro rank

Product category

Interventional Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Vascular embolization devices
• Medical adhesives
• Varicose vein treatment
• Biocompatible polymers
• Interventional medical devices

Headquarters

HQ city

Gyeongju

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales: ENGAIN generates revenue through the sale of medical devices including embolic agents, medical adhesives, wound closure products, and varicose vein treatment systems. Products are sold domestically in Korea and exported internationally. The company operates as both manufacturer and seller with in-house capabilities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

ENGAIN researches, develops, and manufactures proprietary biocompatible polymer-based medical devices for interventional procedures, sold directly to hospitals and healthcare facilities. Its product portfolio covers vascular embolization agents (EGgel, KIPZA, EGbead), medical skin adhesives (EGglue, EasyGlue), the NUVENA NTNT varicose vein treatment system, and single-use medical consumables (Soft Fix PLUS, Bougie-36, LAPA FIX). All products are produced in-house at KGMP-certified facilities and protected by MFDS regulatory approvals.

Product overview

ENGAIN is a medical device research, development, and manufacturing company specializing in biocompatible polymer synthetic materials. The product portfolio consists of three main therapeutic areas: (1) Embolization products including EGgel, KIPZA, and EGbead for vascular embolization procedures, (2) Medical adhesives including EGglue and Easyglue for skin and epidermal closure, and (3) Varicose vein treatment systems including NUVENA using NTNT (Non-thermal, Non-tumescent) adhesive technology. Additionally, the company produces single-use medical consumables including drain tube fixation devices (Soft Fix PLUS), Bougie-36 surgical guides, and LAPA FIX laparoscopic instruments. All products are developed using proprietary polymer chemistry technology and manufactured in-house at KGMP-certified facilities.

Differentiator

Problem solved

Functional benefit

Brands

• KIPZA: Quick-dissolving microparticles for embolization therapy, 100-4,000 μm in 5 size ranges, dissolves within 24 hours
• EGbead
• NUVENA
• EGglue
• EGgel

Products and services

• EGgel (Vascular Embolization Prosthesis) Gelatin-based embolic prosthesis in dry powder form for intravascular embolization procedures, available in 8 particle size options from 50 to 4,000 μm in both particle and cube forms, supplied in 20 mL transparent syringes with 100 mg or 300 mg doses. For use by interventional radiologists and vascular surgeons in hospitals.
• KIPZA (Fast-Dissolving Embolic Microparticles) Fast-degradable microparticle embolic material for vascular embolization that biodegrades within 24 hours, available in 5 size ranges from 100 to 4,000 μm in 20 mL syringes at 100, 130, or 160 mg doses. For use by interventional specialists in hospitals.
• EGbead (Vascular Embolization Microbead) Fast-degradable microbead embolic material for vascular embolization procedures in 2 size ranges from 100 to 500 μm, supplied in 20 mL transparent syringes with 100, 200, or 300 mg doses. For use by interventional radiologists in hospitals.
• EGglue (Medical Skin Adhesive) N-Butyl Cyanoacrylate (n-BCA) based skin adhesive for epidermal closure featuring biocompatibility and strong tensile strength, supplied as a 0.7 mL ampule with applicator in Soft/Narrow tip variants and dyed purple for easy identification. For use by clinicians in hospitals and clinics.
• EasyGlue (이지글루) Medical Skin Adhesive Medical skin adhesive product for wound closure and skin adhesion applications, launched in October 2021 as a companion offering to EGglue.
• NUVENA Varicose Vein Treatment System N-Butyl Cyanoacrylate (n-BCA) based lower extremity varicose vein treatment system with integrated adhesive and injection kit. Uses NTNT (Non-thermal, Non-tumescent) treatment method, developed with 100% domestic Korean technology, providing precision adhesive delivery for consistent occlusion effects. For use by vascular surgeons and interventional phlebologists in hospitals.
• Soft Fix PLUS (Drain Tube Fixator) Silicone and hydrocolloid drain tube fixation device with one-touch locking mechanism to prevent tube twisting, sized for 7-12 Fr drainage tubes with 108 x 48 mm dressing, 25 pieces per box, sterile single-use medical device. For use in hospital surgical and drainage procedures.
• Bougie-36 Surgical Guide Invasive disposable medical guide made of medical silicone, used during gastrectomy to confirm stomach position and guide surgical site marking. Class 2 device, 10 pieces per box, sterile. For use by surgeons in hospitals.
• LAPA FIX Laparoscopic Instrument Disposable general endoscope instrument made of medical silicone that provides surgical space and visibility during laparoscopic procedures by lifting organs against the diaphragm using suction force. Available in 2 sizes (045, 055), 10 pieces per box. For use by laparoscopic surgeons in hospitals.

Quantifiable outcome

• Reduced patient recovery time with NTNT (Non-thermal, Non-tumescent) varicose vein treatment
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Terumo:
• Boston Scientific: Boston Scientific acquired BTG and now markets global embolization solutions (Embozene, Onyx). Competes broadly with ENGAIN's vascular embolization portfolio across multiple geographies with established clinical evidence and distribution.

Direct peers

• Merit Medical Systems: Merit Medical is a leading global manufacturer of embolization particles, microcatheters, and vascular interventional devices. Directly comparable to ENGAIN's EGgel/EGbead/KIPZA embolization product line serving interventional radiology procedures.
• Cook Medical: Cook Medical manufactures embolization coils, particles, and vascular devices used in interventional radiology. Directly competes with ENGAIN's EGgel/KIPZA/EGbead embolic products in hospital interventional settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCWqoHMq7RyAgQ13j4WQxHPQ
• Facebookfacebook.com/engain.official
• Instagraminstagram.com/engain_official

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENGAIN